Calidi Biotherapeutics, Inc.

CLDI · AMEX
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$22,209-$29,216-$25,427-$10,933
Dep. & Amort.$1,535$1,256$260$153
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,957$4,809$0$1,327
Change in WC-$1,698-$6,242$3,569$1,097
Other Non-Cash-$279$2,410$8,384$582
Operating Cash Flow-$19,694-$26,983-$13,214-$7,774
Investing Activities
PP&E Inv.$0-$585-$428-$206
Net Acquisitions$0$9$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$190,011$0
Other Inv. Act.-$16$98-$190,077-$9
Investing Cash Flow-$16-$478-$494-$215
Financing Activities
Debt Repay.$1,918$899$1,381$1,750
Stock Issued$18,065$2,763$10,764$35
Stock Repurch.$0$0$0$0
Dividends Paid-$1,671$0$0$0
Other Fin. Act.$9,053$25,382-$58$8,025
Financing Cash Flow$27,365$29,044$12,087$9,810
Forex Effect-$13-$6$1,030-$4
Net Chg. in Cash$7,642$1,577-$591$1,817
Supplemental Information
Beg. Cash$2,167$590$1,063$420
End Cash$9,809$2,167$472$2,237
Free Cash Flow-$19,710-$27,568-$13,642-$7,980
Calidi Biotherapeutics, Inc. (CLDI) Financial Statements & Key Stats | AlphaPilot